Pancreatic Cancer Research

ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years

Jianhua Zhang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5412-9860; OpenAlex author ID A5100434755. Sources: OpenAlex.

Their work

Papers
12 (first author 2, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
55
Papers, trials and grants by year

2014: 2 papers · 2015: 1 paper · 2016: none · 2017: 3 papers · 2018: none · 2019: none · 2020: 3 papers · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: 1 paper

Papers 12

  1. Clonal dominance defines metastatic dissemination in pancreatic cancer. Co-author DOI 10.1126/sciadv.add9342↗
  2. Prognostic signature construction of energy metabolism-related genes in pancreatic cancer. First author DOI 10.3389/fonc.2022.917897↗
  3. USP21 deubiquitinase elevates macropinocytosis to enable oncogenic KRAS bypass in pancreatic cancer. Co-author DOI 10.1101/gad.348787.121↗
  4. Combination of PD-1 Inhibitor and OX40 Agonist Induces Tumor Rejection and Immune Memory in Mouse Models of Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2020.03.018↗
  5. Oncogenic KRAS-Driven Metabolic Reprogramming in Pancreatic Cancer Cells Utilizes Cytokines from the Tumor Microenvironment. Co-author DOI 10.1158/2159-8290.cd-19-0297↗
  6. Tumor Microenvironment Remodeling Enables Bypass of Oncogenic KRAS Dependency in Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-19-0597↗
  7. Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer. Co-author DOI 10.1038/nature21064↗
  8. 4-1BB Agonist Focuses CD8+ Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-17-0831↗
  9. Sclareolide enhances gemcitabine‑induced cell death through mediating the NICD and Gli1 pathways in gemcitabine‑resistant human pancreatic cancer. Last author DOI 10.3892/mmr.2017.6182↗
  10. miR-15b promotes epithelial-mesenchymal transition by inhibiting SMURF2 in pancreatic cancer. First author DOI 10.3892/ijo.2015.3076↗
  11. Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer. Co-author DOI 10.1016/j.cell.2014.06.003↗
  12. Identification of double-stranded genomic DNA spanning all chromosomes with mutated KRAS and p53 DNA in the serum exosomes of patients with pancreatic cancer. Co-author DOI 10.1074/jbc.c113.532267↗

Closest collaborators

The 25 strongest of 55 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Anirban Maitra · 5 shared papers, 2017–2024 · strength 0.41
  2. Ronald Anthony Depinho · 5 shared papers, 2014–2021 · strength 0.35
  3. Haoqiang Ying · 4 shared papers, 2014–2024 · strength 0.28
  4. Timothy Paul Heffernan · 4 shared papers, 2014–2024 · strength 0.26
  5. Giannicola Genovese · 3 shared papers, 2017–2024 · strength 0.25
  6. Huamin Wang · 4 shared papers, 2014–2020 · strength 0.25
  7. Andrea Viale · 3 shared papers, 2014–2024 · strength 0.21
  8. Giulio Francesco Draetta · 3 shared papers, 2014–2024 · strength 0.21
  9. Pingping Hou · 2 shared papers, 2020–2021 · strength 0.20
  10. Alessandro Carugo · 2 shared papers, 2017–2024 · strength 0.18
  11. Virginia Giuliani · 2 shared papers, 2017–2024 · strength 0.18
  12. Phillip Andrew Futreal · 2 shared papers, 2014–2024 · strength 0.17
  13. Hao Liu · 1 shared paper, 2022 · strength 0.16
  14. Yuxiang Zhao · 1 shared paper, 2022 · strength 0.16
  15. Wantong Yao · 2 shared papers, 2014–2021 · strength 0.14
  16. Francesca Citron · 1 shared paper, 2024 · strength 0.13
  17. I-Lin Ho · 1 shared paper, 2024 · strength 0.13
  18. Ziheng Chen · 1 shared paper, 2024 · strength 0.13
  19. Michael P. Kim · 1 shared paper, 2024 · strength 0.13
  20. Raghu Kalluri · 2 shared papers, 2014–2020 · strength 0.13
  21. Vincent Bernard · 2 shared papers, 2017–2020 · strength 0.13
  22. Avnish Kapoor · 2 shared papers, 2014–2020 · strength 0.12
  23. Prasenjit Dey · 2 shared papers, 2017–2020 · strength 0.12
  24. Lynda Chin · 3 shared papers, 2014–2017 · strength 0.11
  25. Yan Liang · 1 shared paper, 2021 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.